NCT04464798

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas.

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Celgene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification. Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion).

Conditions

• Lymphoma

Interventions

Type	Name	Description
DRUG	CC-220	Oral
DRUG	Rituximab	SC and IV infusion
DRUG	Obinutuzumab	IV Infusion

Timeline

• Start date: 2020-11-11
• Primary completion: 2023-01-31
• Completion: 2025-01-09
• First posted: 2020-07-09
• Last updated: 2025-04-29

Locations

26 sites across 6 countries: United States, France, Germany, Italy, South Korea, Taiwan

Regulatory

• FDA-regulated drug study